1[1]Richards MA, Hopwood P, Ramirez AJ, et al. Doxorubicin in advanced breast cancer: influence of schedule on response, survival and quality of life. Eur J Cancer 1992, 28: 1023.
2[2]Fumoleau P, Delgado MA, Delozier T, et al. Phase Ⅱtrial of weekly intravenous vinorelbine in first-line advanced breast cancer chemothrapy. J Clin Oncol,1993, 11: 1245.
3[3]Miller AB, Hoogstraten B, Straquet M, et al. Reporting results of cancer treatment. Cancer, 1981, 47:207.
4[4]Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol, 1997, 15: 2483.
5[5]Spielmann M, Dorval T, Turpin F,et al. Phase Ⅱ trial of vinorelbine/doxorubicin as first-line therapy of advanced breast cancer. J Clin Oncol, 1994, 12: 1764.
6[6]Hochster HS. Combined doxorubicin/vinorelbine (Navelbine) therapy in the treatment of advanced breast cancer. Semin Oncol, 1995, 22(2 suppl 5): 55.
7[1]Pierga JY, Mouret E, Dieras V, et al. Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer[J]. Br J Cancer, 2000,83(11): 1480-1487.
8[2]Chollet P, Charrier S, Brain E. Clinical and pathological response to primary chemotherapy in operable breast cancer[J]. Eur J Cancer, 1997,33(6):862-866.
9[3]Recht A.Locally advanced breast cancer and postmastectomy radiotherapy[J]. Surg Oncol Clin N Am, 2000,9(3):603-620.
10[4]Inaji H, Komoike Y, Motomura K, et al. Breast-conserving treatment after neoadjuvant chemotherapy in large breast cancer[J]. Breast Cancer,2002,9(1):20-25.
